Evaluating the benefit of HOCL based treatment in managing dry eye disease and meibomian gland dysfunction

Assessing the Effectiveness of 0.01 percent HOCL Interventions in Managing Ocular Surface Disorders: Randomized Trials on Dry Eye Disease and Meibomian Gland Dysfunction - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076967

Enrollment

270

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H041- Other disorders of lacrimal gland Health Condition 2: H028- Other specified disorders of eyelid

Interventions

Intervention1: 0.01% hypochlorous acid eye drops and 0.05% carboxymethyl cellulose eye drops: dosage for 0.01% hypochlorous acid eye drops will be four times a day for a period of three months. dosage

Eligibility

Inclusion criteria

Inclusion criteria: for dry eye disease patients- -Patient age between 18-70 years -Cases with no history of prior ocular surgery for past six month. for Meibomian gland dysfunction patients- -Patient age between 18-70 years -Cases with no history of prior ocular surgery for past six months

Exclusion criteria

Exclusion criteria: for dry eye disease patients- -Patient age below 18 years -Pregnant or lactating females -Any prior ocular surgery in past six months -Those with ocular problems such as ocular allergy, and nasolacrimal sac problems; those who are using a punctual plug or contact lenses - unwilling to participate for Meibomian gland dysfunction patients- -Patient age below 18 years -Pregnant or lactating females -Any prior ocular surgery in past six months -Those with ocular problems such as ocular allergy, and nasolacrimal sac problems; those who are using a punctual plug or contact lenses - unwilling to participate

Design outcomes

Primary

Measure	Time frame
for dry eye disease- percentage change in OSDI score for Meibomian gland dysfunction : percentage change in the total MGD grading scale score.Timepoint: for both dry eye disease and Meibomian gland dysfunction- day 0, day 15, day 30, day 60, day 90	—

Secondary

Measure	Time frame
For both dry eye disease and Meibomian gland dysfunction- patient preference, adherence and safety.Timepoint: day 0, day 15, day 30, day 60 , day 90	—

Countries

India

Contacts

Public ContactDr Namrata Sharma

AIIMS, New Delhi

namrata.sharma@gmail.com9868398412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026